Marshall Wace
IPSC icon

Marshall Wace’s Century Therapeutics IPSC Stock Holding History

Marshall Wace’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
537,994
-135,590
-20% -$310K ﹤0.01% 2064
2026
Q1 		$1.52M Buy
+673,584
New +$1.42M ﹤0.01% 1932
2025
Q4 		– Sell
-54,161
Closed -$27.1K – 3192
2025
Q3 		$27.1K Sell
54,161
-85,546
-61% -$46.1K ﹤0.01% 2770
2025
Q2 		$78.2K Buy
+139,707
New +$75K ﹤0.01% 2566
2025
Q1 		– Sell
-35,511
Closed -$35.9K – 2849
2024
Q4 		$35.9K Buy
+35,511
New +$48.3K ﹤0.01% 2498
2023
Q2 		– Sell
-110,316
Closed -$383K – 2699
2023
Q1 		$383K Buy
110,316
+52,818
+92% +$232K ﹤0.01% 2212
2022
Q4 		$295K Sell
57,498
-643,840
-92% -$6.08M ﹤0.01% 2575
2022
Q3 		$6.94M Hold
701,338
– – 0.02% 1144
2022
Q2 		$5.89M Hold
701,338
– – 0.01% 1226
2022
Q1 		$8.83M Hold
701,338
– – 0.02% 963
2021
Q4 		$11.1M Buy
701,338
+589,786
+529% +$11.1M 0.02% 793
2021
Q3 		$2.81M Buy
111,552
+58,803
+111% +$1.59M 0.01% 1308
2021
Q2 		$1.55M Buy
+52,749
New +$1.34M 0.01% 1585

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Marshall Wace's IPSC Position: Q2 2026 in Review

Marshall Wace reduced its Century Therapeutics (IPSC) stake by 20% in Q2 2026, selling an estimated $310K and leaving 537,994 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2064.

Marshall Wace first reported a position in IPSC in Q2 2021 and has held it in 13 quarters since. The position peaked at $11.1M in Q4 2021. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Marshall Wace held 537,994 shares of Century Therapeutics worth $1.32M as of Q2 2026.
  • Marshall Wace sold 135,590 Century Therapeutics shares in Q2 2026, an estimated $310K.
  • Century Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2064 holding.
  • Marshall Wace first reported a position in Century Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • Marshall Wace's Century Therapeutics position peaked at $11.1M in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.